Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...

If there’s one Royal couple that seems to be going strong, it’s Prince Harry and Meghan Markle. Even as rumors swirl about ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a prominent player in the pharmaceuticals industry with a market capitalization of $735 billion and impressive revenue growth of 37% over the last ...

Lily Allen's 'West End Girl' is a portrayal of modern love and loss that's made listeners reassess their own experiences ...

Eli Lilly's CDK4/6 inhibitor Verzenio reduced the risk of death by 15.8% when used as adjuvant treatment for early-stage HR-positive, HER2-negative breast cancer, according the reveal of data from the ...

Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it will, even if it beats analysts' estimates. The best approach is to take a ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2-, high-risk early breast cancer Seven-year results from the ...